After $-0.17 EPS was announced last quarter, analysts now see EPS growth of -17.65 % for Moleculin Biotech, Inc. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06, Bloomberg Earnings reports. The company had a trading volume of 174,300 shares, compared to its average volume of 759,656.
Earnings report for Moleculin Biotech, Inc.
MBRX has been the subject of several research reports. MBRX has 9,070 shares volume. The stock outperformed the S&P 500 by 59.09%.
More recent Moleculin Biotech, Inc.
Zacks Investment Research downgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a buy rating to a hold rating in a report released on Saturday, April 21st.
Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates.The company has $44.46 million market cap. The Company's lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia.now it has negative earnings. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. And last was announced on May 03, 2018, called "Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial".
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.